MHRA licence donanemab for use in the UK. NICE publish draft guidance not recommending it for NHS use
Another of the new generation of drugs to treat Alzheimer’s disease, donanemab, has been licenced by the Medicines and Healthcare products Regulatory Agency (MHRA) for prescription by doctors in Britain. Read more about the MHRA decision here: https://www.gov.uk/government/news/donanemab-licensed-for-early-stages-of-alzheimers-disease-in-adult-patients-who-have-one-or-no-copies-of-apolipoprotein-e4-gene The National Institute for Health and Care Excellence (NICE), however, has published draft guidance for consultation not…